

---

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934  
(Amendment No. 4)\*

**Beam Therapeutics Inc.**

---

(Name of Issuer)

**Common Stock par value \$0.01 per share**

---

(Title of Class of Securities)

**07373V105**

---

(CUSIP Number)

**03/31/2025**

---

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)  
 Rule 13d-1(c)  
 Rule 13d-1(d)

---

SCHEDULE 13G

CUSIP No. 07373V105

Names of Reporting Persons

1

ARCH Venture Fund IX, L.P.

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

	Sole Voting Power
5	0.00
Number of Shares Beneficially Owned by Each Reporting Person With:	Shared Voting Power
6	4,540,132.00
	Sole Dispositive Power
7	0.00
	Shared Dispositive Power
8	4,540,132.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	4,540,132.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	<input type="checkbox"/>
11	Percent of class represented by amount in row (9)
	4.5 %
12	Type of Reporting Person (See Instructions)
	PN

## SCHEDULE 13G

**CUSIP No.** 07373V105

1	Names of Reporting Persons
	ARCH Venture Fund IX Overage, L.P.
	Check the appropriate box if a member of a Group (see instructions)
2	<input type="checkbox"/> (a)
	<input type="checkbox"/> (b)
3	Sec Use Only
4	Citizenship or Place of Organization
	DELAWARE
	Sole Voting Power
5	0.00
Number of Shares Beneficially Owned by Each Reporting Person With:	Shared Voting Power
6	4,540,132.00
	Sole Dispositive Power
7	0.00
	Shared Dispositive Power
8	4,540,132.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	4,540,132.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	<input type="checkbox"/>

11 Percent of class represented by amount in row (9)  
4.5 %  
Type of Reporting Person (See Instructions)  
12  
PN

## SCHEDULE 13G

**CUSIP No.** 07373V105

Names of Reporting Persons

1 ARCH Venture Partners IX, L.P.  
Check the appropriate box if a member of a Group (see instructions)

2  (a)  
 (b)

3 Sec Use Only

Citizenship or Place of Organization

4 DELAWARE

Sole Voting Power

5  
0.00

Number of  
Shares  
Beneficially

6  
4,540,132.00

Owned by  
Each  
Reporting

7  
0.00

Person  
With:  
Shared Dispositive  
Power

8  
4,540,132.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9  
4,540,132.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11  
4.5 %

Type of Reporting Person (See Instructions)

12  
PN

## SCHEDULE 13G

**CUSIP No.** 07373V105

Names of Reporting Persons

1 ARCH Venture Partners IX Overage, L.P.

2 Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

3 Sec Use Only  
Citizenship or Place of Organization

4 DELAWARE

Sole Voting Power

5

0.00

Number of Shares Beneficially Owned by Each Reporting Person With:

Shared Voting Power

6

4,540,132.00

Sole Dispositive Power

7

0.00

Shared Dispositive

8

Power

4,540,132.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

4,540,132.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

4.5 %

Type of Reporting Person (See Instructions)

12

PN

## SCHEDULE 13G

**CUSIP No.** 07373V105

Names of Reporting Persons

1

ARCH Venture Partners IX, LLC

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3 Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5

0.00

Shared Voting Power

6

4,540,132.00

Sole Dispositive Power

7

0.00

8 Shared Dispositive

Power

4,540,132.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

4,540,132.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

4.5 %

Type of Reporting Person (See Instructions)

12

OO

### SCHEDULE 13G

CUSIP No. 07373V105

Names of Reporting Persons

1

Keith Crandell

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

UNITED STATES

Sole Voting Power

5

17,730.00

Number of Shares

Shared Voting Power

Beneficially Owned by Each Reporting Person

6

4,540,132.00

Sole Dispositive Power

7

17,730.00

With:

Shared Dispositive

8

Power

4,540,132.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

4,557,862.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

4.5 %

Type of Reporting Person (See Instructions)

12

IN

### SCHEDULE 13G

07373V105

**CUSIP No.**

Names of Reporting Persons

1

Clinton Bybee

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

UNITED STATES

Sole Voting Power

5

10,498.00

Number of  
Shares  
Beneficially  
Owned by  
Each  
Reporting  
Person  
With:

Shared Voting Power

6

4,540,132.00

Sole Dispositive Power

7

10,498.00

Shared Dispositive

8

Power

4,540,132.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

4,550,630.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

4.5 %

Type of Reporting Person (See Instructions)

12

IN

**SCHEDULE 13G**

**CUSIP No.** 07373V105

Names of Reporting Persons

1

Robert Nelsen

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

UNITED STATES

Sole Voting Power

5

60,615.00

Number of  
Shares  
Beneficially  
Owned by  
Each

Shared Voting Power

6

Reporting Person 4,540,132.00  
 With: Sole Dispositive Power  
 7  
 60,615.00  
 Shared Dispositive Power  
 8  
 4,540,132.00  
 Aggregate Amount Beneficially Owned by Each Reporting Person  
 9  
 4,600,747.00  
 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)  
 10  
  
 Percent of class represented by amount in row (9)  
 11  
 4.6 %  
 Type of Reporting Person (See Instructions)  
 12  
 IN

## SCHEDULE 13G

### Item 1.

Name of issuer:

(a) Beam Therapeutics Inc.

Address of issuer's principal executive offices:

(b) 238 Main Street, Cambridge, MA 02142

### Item 2.

Name of person filing:

(a) ARCH Venture Fund IX, L.P. ("AVF IX"); ARCH Venture Partners IX, L.P. ("AVP IX LP"); ARCH Venture Partners IX, LLC ("AVP IX LLC"); ARCH Venture Fund IX Overage, L.P. ("AVF IX Overage"); ARCH Venture Partners IX Overage, L.P. ("AVP IX Overage GP") (collectively, the "Reporting Entities" and individually, each a "Reporting Entity"); and Keith Crandell ("Crandell"), Robert Nelsen ("Nelsen") and Clinton Bybee ("Bybee") (collectively, the "Managing Directors" and individually, each a "Managing Director"). The Reporting Entities and the Managing Directors collectively are referred to as the "Reporting Persons".

Address or principal business office or, if none, residence:

(b) 8755 W. Higgins Avenue, Suite 1025, Chicago, IL 60631

Citizenship:

(c) Each of AVF IX, AVP IX LP, AVF IX Overage and AVP IX Overage GP, are limited partnerships organized under the laws of the State of Delaware. AVP IX LLC is a limited liability company organized under the laws of the State of Delaware. Each Managing Director is a US citizen.

Title of class of securities:

(d) Common Stock par value \$0.01 per share

CUSIP No.:

(e) 07373V105

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a)  Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);  
 (b)  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);  
 (c)  Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);  
 (d)  Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);  
 (e)  An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

- (f)  An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
- (g)  A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
- (h)  A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i)  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
- (j)  Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 5. Ownership of 5 Percent or Less of a Class.

- Ownership of 5 percent or less of a class

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

Not Applicable

#### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

ARCH Venture Fund IX, L.P.

Signature: ARCH Venture Partners IX, L.P.

Name/Title: its General Partner

Date: 05/15/2025

Signature: ARCH Venture Partners IX, LLC

Name/Title: its General Partner

Date: 05/15/2025

Signature: /s/ Mark McDonnell

Name/Title: \* Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director

Date: 05/15/2025

ARCH Venture Fund IX Overage, L.P.

Signature: ARCH Venture Partners IX Overage, L.P.

Name/Title: its General Partner

Date: 05/15/2025

Signature: ARCH Venture Partners IX, LLC

Name/Title: its General Partner

Date: 05/15/2025

Signature: /s/ Mark McDonnell

Name/Title: \* Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director

Date: 05/15/2025

ARCH Venture Partners IX, L.P.

Signature: ARCH Venture Partners IX, LLC

Name/Title: its General Partner

Date: 05/15/2025

Signature: /s/ Mark McDonnell

Name/Title: \* Mark McDonnell, as Attorney-in-Fact for Keith  
Crandell, Managing Director

Date: 05/15/2025

ARCH Venture Partners IX Overage, L.P.

Signature: ARCH Venture Partners IX, LLC

Name/Title: its General Partner

Date: 05/15/2025

Signature: /s/ Mark McDonnell

Name/Title: \* Mark McDonnell, as Attorney-in-Fact for Keith  
Crandell, Managing Director

Date: 05/15/2025

ARCH Venture Partners IX, LLC

Signature: /s/ Mark McDonnell

Name/Title: \* Mark McDonnell, as Attorney-in-Fact for Keith  
Crandell, Managing Director

Date: 05/15/2025

Keith Crandell

Signature: /s/ Mark McDonnell

Name/Title: \* Mark McDonnell, as Attorney-in-Fact for Keith  
Crandell

Date: 05/15/2025

Clinton Bybee

Signature: /s/ Mark McDonnell

Name/Title: \* Mark McDonnell, as Attorney-in-Fact for  
Clinton Bybee

Date: 05/15/2025

Robert Nelsen

Signature: /s/ Mark McDonnell

Name/Title: \* Mark McDonnell, as Attorney-in-Fact for  
Robert Nelsen

Date: 05/15/2025

**Comments accompanying signature:** \* This Schedule 13G was executed by Mark McDonnell pursuant to a Power of Attorney filed as Exhibit 24 to the Form 3 relating to the beneficial ownership of shares of Beam Therapeutics, Inc. by the Reporting Persons filed with the Securities Exchange Commission on February 5, 2020 and incorporated herein in its entirety by reference.

AGREEMENT

Pursuant to Rule 13d-1-(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of stock of Beam Therapeutics, Inc.

This Agreement may be executed in any number of counterparts, each of which shall be deemed an original.

Dated: May 15, 2025

ARCH VENTURE FUND IX, L.P.

By: ARCH Venture Partners IX, L.P.  
its General Partner

By: ARCH Venture Partners IX, LLC  
its General Partner

By: \_\_\_\_\_  
\*  
Keith Crandell  
Managing Director

ARCH VENTURE PARTNERS IX, L.P.

By: ARCH Venture Partners IX, LLC  
its General Partner

By: \_\_\_\_\_  
\*  
Keith Crandell  
Managing Director

ARCH VENTURE PARTNERS IX, LLC

By: \_\_\_\_\_  
\*  
Keith Crandell  
Managing Director

ARCH VENTURE FUND IX OVERAGE, L.P.

By: ARCH Venture Partners IX Overage, L.P.  
its General Partner

By: ARCH Venture Partners IX, LLC  
its General Partner

By: \_\_\_\_\_  
\*  
Keith Crandell  
Managing Director

ARCH VENTURE PARTNERS IX OVERAGE, L.P.

By: ARCH Venture Partners IX, LLC  
its General Partner

By: \_\_\_\_\_  
\*  
Keith Crandell  
Managing Director

\_\_\_\_\_  
\*  
Keith Crandell

\_\_\_\_\_  
\*  
Robert Nelsen

\_\_\_\_\_  
\*  
Clinton Bybee

\* By: /s/ Mark McDonnell  
Mark McDonnell as  
Attorney-in-Fact

\* This Agreement of Joint Filing was executed by Mark McDonnell pursuant to a Power of Attorney filed as Exhibit 24 to the Form 3 relating to the beneficial ownership of shares of Beam Therapeutics, Inc. by the Reporting Persons filed with the Securities Exchange Commission on February 5, 2020 and incorporated herein in its entirety by reference.

---